DK2990798T3 - Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål - Google Patents
Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål Download PDFInfo
- Publication number
- DK2990798T3 DK2990798T3 DK15186647T DK15186647T DK2990798T3 DK 2990798 T3 DK2990798 T3 DK 2990798T3 DK 15186647 T DK15186647 T DK 15186647T DK 15186647 T DK15186647 T DK 15186647T DK 2990798 T3 DK2990798 T3 DK 2990798T3
- Authority
- DK
- Denmark
- Prior art keywords
- hngal
- lcn2
- muteins
- affinity
- specific target
- Prior art date
Links
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 title 2
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 title 1
- 102000047202 human LCN2 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26709809P | 2009-12-07 | 2009-12-07 | |
| EP10784824.4A EP2510357B1 (en) | 2009-12-07 | 2010-12-07 | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2990798T3 true DK2990798T3 (da) | 2019-12-02 |
Family
ID=43597993
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15186647T DK2990798T3 (da) | 2009-12-07 | 2010-12-07 | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål |
| DK10784824.4T DK2510357T3 (da) | 2009-12-07 | 2010-12-07 | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet til et specifikt mål |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10784824.4T DK2510357T3 (da) | 2009-12-07 | 2010-12-07 | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet til et specifikt mål |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9549968B2 (da) |
| EP (3) | EP2990798B1 (da) |
| JP (5) | JP5913120B2 (da) |
| KR (2) | KR101842076B1 (da) |
| CN (1) | CN102770764B (da) |
| AU (1) | AU2010329995B2 (da) |
| BR (1) | BR112012013662B1 (da) |
| CA (1) | CA2779562C (da) |
| DK (2) | DK2990798T3 (da) |
| RU (2) | RU2564125C2 (da) |
| SG (1) | SG10201408073XA (da) |
| WO (1) | WO2011069992A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2990798T3 (da) | 2009-12-07 | 2019-12-02 | Pieris Pharmaceuticals Gmbh | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål |
| SG10201505785QA (en) * | 2010-08-16 | 2015-09-29 | Pieris Ag | Binding proteins for hepcidin |
| EP2809679A1 (en) | 2012-01-31 | 2014-12-10 | Technische Universität München | Muteins of a1m lipocalin and method of production therefor |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3789397B1 (en) | 2014-05-22 | 2023-12-06 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| KR20170142200A (ko) * | 2015-05-04 | 2017-12-27 | 피어이스 파마슈티컬즈 게엠베하 | Cd137에 특이적인 신규한 단백질 |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| MX2017014730A (es) * | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| MX2017014716A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Polipeptido de fusion anti-cancer. |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| MX2018006559A (es) * | 2015-11-30 | 2019-06-12 | Pieris Australia Pty Ltd | Nuevos polipeptidos de fusion anti-angiogenicos. |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| US20190257832A1 (en) | 2016-07-18 | 2019-08-22 | Philippe Ulsemer | Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors |
| GB201615254D0 (en) | 2016-09-08 | 2016-11-23 | Ge Healthcare Bio Sciences Ab | Novel Ligand and use thereof |
| CN107403074B (zh) * | 2017-06-09 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种突变蛋白的检测方法及装置 |
| EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
| AU2020253034A1 (en) | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| KR100384353B1 (ko) | 1994-05-18 | 2003-10-04 | 네크타르 테라퓨틱스 | 인터페론의건조분말제형을제조하기위한방법및조성물 |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
| EP1009762A2 (en) | 1997-08-06 | 2000-06-21 | ZymoGenetics, Inc. | Lipocalin homologs |
| US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
| DE19742706B4 (de) * | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| IL139786A0 (en) | 1998-06-08 | 2002-02-10 | Hoffmann La Roche | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6566073B1 (en) | 1998-10-19 | 2003-05-20 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| CN1279053C (zh) * | 1999-03-04 | 2006-10-11 | 普雷西斯药品公司 | 含有D－氨基酸的β－淀粉样肽聚集的调节因子 |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| CN105112477A (zh) * | 2006-08-01 | 2015-12-02 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| JP5848006B2 (ja) * | 2007-10-19 | 2016-01-27 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | Ｎｇａｌの検出用イムノアッセイ及びキット |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| DK2990798T3 (da) | 2009-12-07 | 2019-12-02 | Pieris Pharmaceuticals Gmbh | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål |
| SG10201505785QA (en) * | 2010-08-16 | 2015-09-29 | Pieris Ag | Binding proteins for hepcidin |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| EP2920202B1 (en) * | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| KR20170142200A (ko) | 2015-05-04 | 2017-12-27 | 피어이스 파마슈티컬즈 게엠베하 | Cd137에 특이적인 신규한 단백질 |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2010
- 2010-12-07 DK DK15186647T patent/DK2990798T3/da active
- 2010-12-07 EP EP15186647.2A patent/EP2990798B1/en active Active
- 2010-12-07 CN CN201080055370.5A patent/CN102770764B/zh active Active
- 2010-12-07 US US13/514,133 patent/US9549968B2/en active Active
- 2010-12-07 RU RU2012128586/10A patent/RU2564125C2/ru active
- 2010-12-07 AU AU2010329995A patent/AU2010329995B2/en active Active
- 2010-12-07 JP JP2012542505A patent/JP5913120B2/ja active Active
- 2010-12-07 WO PCT/EP2010/069028 patent/WO2011069992A2/en active Application Filing
- 2010-12-07 EP EP10784824.4A patent/EP2510357B1/en active Active
- 2010-12-07 DK DK10784824.4T patent/DK2510357T3/da active
- 2010-12-07 KR KR1020127017730A patent/KR101842076B1/ko active IP Right Grant
- 2010-12-07 RU RU2015137158A patent/RU2707126C2/ru active
- 2010-12-07 SG SG10201408073XA patent/SG10201408073XA/en unknown
- 2010-12-07 BR BR112012013662-3A patent/BR112012013662B1/pt active IP Right Grant
- 2010-12-07 EP EP19198835.1A patent/EP3660510A3/en active Pending
- 2010-12-07 CA CA2779562A patent/CA2779562C/en active Active
- 2010-12-07 KR KR1020187007781A patent/KR101974044B1/ko active IP Right Grant
-
2015
- 2015-12-02 JP JP2015236010A patent/JP6346159B2/ja active Active
-
2016
- 2016-12-15 US US15/380,168 patent/US10618941B2/en active Active
-
2018
- 2018-05-24 JP JP2018099240A patent/JP2018148914A/ja active Pending
-
2020
- 2020-03-06 US US16/812,069 patent/US11827681B2/en active Active
- 2020-07-07 JP JP2020117175A patent/JP2021006024A/ja active Pending
-
2022
- 2022-07-01 JP JP2022106985A patent/JP7482544B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2990798T3 (da) | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål | |
| CY2018003I2 (el) | Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4 | |
| BRPI0907676A2 (pt) | Composição, uso de uma composição e método de transferência de calor | |
| DK3381933T3 (da) | Muteiner af hngal og relaterede proteiner med affinitet til et givet mål | |
| DK2152250T3 (da) | Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse | |
| BR112013001571A2 (pt) | composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40 | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| DK2139987T5 (da) | Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser | |
| DK2257304T3 (da) | Poloxamer med langvarig frigivelse indeholdende farmaceutiske sammensætninger | |
| BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
| BR112013003536A2 (pt) | composição, e utilização de uma composição. | |
| BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
| BRPI0812354A2 (pt) | Composição farmacêutica não-aquosa. | |
| DE602008006709D1 (de) | Funduskamera | |
| BRPI0914793A2 (pt) | Composição, e, uso de uma composição | |
| DE602009001205D1 (de) | Parallelmechanismus mit verbessertes Kugelgelenk | |
| BR112013006165A2 (pt) | composição de revestimento à base d'água | |
| BRPI1012250A2 (pt) | composição lubrificante, e, uso de uma composição lubrificante | |
| BRPI0916575A2 (pt) | composição de graxa lubrificante, e, uso de uma composição de graxa lubrificante | |
| BRPI0905913A2 (pt) | "polipeptídeos, composição para detectar um microorganismo alvo e métodos para detectar um microorganismo alvo" | |
| BRPI0917016A2 (pt) | composição lubrificante, e, uso de uma composição lubrificante | |
| BRPI1006953A2 (pt) | composição farmacêutica, e, uso de uma composição | |
| BRPI0913297A2 (pt) | composição, farmacêutica, uso de uma composição, e, kit terapêutico. | |
| DK2323686T3 (da) | Adiponectin til behandling af lungesygdom | |
| BRPI1007023A2 (pt) | composição lubrificante, e, uso de uma composição lubrificante |